- Home
- TBPH vs SLI Comparison
TBPH vs SLI Comparison
Compare TBPH & SLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBPH
- SLI
- Stock Information
- Founded
- TBPH 2013
- SLI 1998
- Country
- TBPH United States
- SLI Canada
- Employees
- TBPH N/A
- SLI N/A
- Industry
- TBPH Biotechnology: Pharmaceutical Preparations
- SLI Major Chemicals
- Sector
- TBPH Health Care
- SLI Industrials
- Exchange
- TBPH Nasdaq
- SLI Nasdaq
- Market Cap
- TBPH 485.8M
- SLI 406.1M
- IPO Year
- TBPH N/A
- SLI N/A
- Fundamental
- Price
- TBPH $9.59
- SLI $1.47
- Analyst Decision
- TBPH Buy
- SLI Strong Buy
- Analyst Count
- TBPH 4
- SLI 2
- Target Price
- TBPH $13.75
- SLI $3.95
- AVG Volume (30 Days)
- TBPH 217.1K
- SLI 1.4M
- Earning Date
- TBPH 11-12-2024
- SLI 02-06-2025
- Dividend Yield
- TBPH N/A
- SLI N/A
- EPS Growth
- TBPH N/A
- SLI N/A
- EPS
- TBPH N/A
- SLI 0.61
- Revenue
- TBPH $63,192,000.00
- SLI N/A
- Revenue This Year
- TBPH $11.41
- SLI N/A
- Revenue Next Year
- TBPH $37.36
- SLI N/A
- P/E Ratio
- TBPH N/A
- SLI $2.35
- Revenue Growth
- TBPH 15.93
- SLI N/A
- 52 Week Low
- TBPH $7.44
- SLI $1.05
- 52 Week High
- TBPH $11.71
- SLI $2.64
- Technical
- Relative Strength Index (RSI)
- TBPH 50.13
- SLI 38.62
- Support Level
- TBPH $9.62
- SLI $1.34
- Resistance Level
- TBPH $10.08
- SLI $1.49
- Average True Range (ATR)
- TBPH 0.31
- SLI 0.10
- MACD
- TBPH -0.06
- SLI -0.01
- Stochastic Oscillator
- TBPH 25.00
- SLI 29.40
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
About SLI Standard Lithium Ltd.
Standard Lithium Corp is engaged in the exploration and development of lithium brine properties in the United States. The company is focused on the exploration and development of the Arkansas Lithium Project, which is located in south-central Arkansas. Its other projects comprise the Lanxess Project, Tetra Project, and Bristol Dry Lake Project.